Table 2. The final table with calculated columns.
The rows are sorted by z-score. Only the top 6 rows are shown (see Supplemental Information 2 for all 162 rows with z < − 1).
| Drug | Serious adverse event | Ds | Dn | Cs | Cn | Control | SE | OR | Lower limit | Upper limit | z | Clinical Trials.gov ID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| V501 | Cervical dysplasia | 20 | 480 | 46 | 468 | Placebo | 0.28 | 0.40 | 0.23 | 0.69 | −3.33 | NCT00378560 |
| Clopidogrel/ Telmisartan | Colon cancer | 4 | 5,000 | 14 | 5,023 | Clopidogrel/ Placebo | 0.57 | 0.29 | 0.09 | 0.87 | −2.20 | NCT00153062 |
| Vorapaxar | RECTAL CANCER | 4 | 13,186 | 13 | 13,166 | Placebo | 0.57 | 0.31 | 0.10 | 0.94 | −2.06 | NCT00526474 |
| Phylloquinone | Cancer | 3 | 217 | 11 | 223 | Placebo | 0.66 | 0.27 | 0.07 | 0.98 | −1.99 | NCT00150969 |
| Clopidogrel + ASA | Pancreatic carcinoma | 1 | 3,772 | 8 | 3,782 | Placebo + ASA | 1.06 | 0.13 | 0.02 | 1.00 | −1.96 | NCT00249873 |
| Core-phase: Aliskiren | Gastric cancer | 1 | 4,272 | 8 | 4,285 | Core-phase: Placebo | 1.06 | 0.13 | 0.02 | 1.00 | −1.96 | NCT00549757 |
Notes.
TITLE
- Ds
- Number of patients with SAE in Drug arm
- Dn
- Number of patients in Drug arm
- Cs
- Number of patients with SAE in Control arm
- Cn
- Number of patients in Control arm
The original indications of the trials were (from top to bottom): HPV Infections, Stroke, Atherosclerosis, Osteoporosis, Atrial Fibrillation, and Type 2 Diabetes.